Profitability
This table compares Northwest Biotherapeutics and Evoke Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Northwest Biotherapeutics | -4,666.29% | N/A | -261.36% |
| Evoke Pharma | -71.32% | -308.49% | -53.66% |
Insider and Institutional Ownership
0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 8.7% of Northwest Biotherapeutics shares are owned by insiders. Comparatively, 6.1% of Evoke Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Northwest Biotherapeutics and Evoke Pharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Northwest Biotherapeutics | $1.93 million | 191.14 | -$62.60 million | ($0.08) | -3.50 |
| Evoke Pharma | $8.62 million | 0.80 | -$7.79 million | ($10.99) | -0.42 |
Risk & Volatility
Northwest Biotherapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.
Summary
Evoke Pharma beats Northwest Biotherapeutics on 6 of the 11 factors compared between the two stocks.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
About Evoke Pharma
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
